Drug
Exenatide clinical trials
Also written Byetta, Bydureon, AC2993 and Exendin-4.
- studies test it
- 231
- open now
- 1
- in phase 3
- 70
- first study started
- 2002
Keep track of what changes. Save the Exenatide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
231 studies that test it; most in 2008 (24)
| Year | Studies |
|---|---|
| 2002 | 7 |
| 2003 | 5 |
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 12 |
| 2007 | 15 |
| 2008 | 24 |
| 2009 | 21 |
| 2010 | 19 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 18 |
| 2014 | 17 |
| 2015 | 17 |
| 2016 | 17 |
| 2017 | 13 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 31
- Phase 2
- 49
- Phase 3
- 70
- Phase 4
- 74
- No phase
- 23
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 10
Who runs them
Industry 83 · Other 148
AstraZeneca (60) · Intarcia Therapeutics (10) · Amsterdam UMC, location VUmc (6) · University College, London (4) · The University of Texas Health Science Center, Houston (4) · The University of Texas Health Science Center at San Antonio (4) · Baylor College of Medicine (4) · Seattle Children's Hospital (3)
Often tested with
Tested in the same studies.
Dapagliflozin (6) · Sitagliptin (6) · Insulin Glargine (5) · Liraglutide (4) · Pioglitazone (3) · Pramlintide (2) · Saline Solution (2) · Oxygen (1)
Studies
Open first, then newest update. How each study uses Exenatide is read from its arms, and is right about nine times in ten.
Testing it · 231
- Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesRecruitingPhase 4Maisa N. Feghali, MDNCT05482789Written as Exenatide
- Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyCompletedPhase 3University Hospital, BordeauxNCT02860923Written as Exenatide
- Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseCompletedPhase 3University College, LondonNCT04232969Written as Exenatide extended release 2mg (Bydureon)
- Exenatide for Smoking Cessation and Prevention of Weight GainCompletedPhase 2The University of Texas Health Science Center, HoustonNCT05610800Written as Exenatide 2 milligram (mg) Injection
- Exenatide For Reducing the Reinforcing Effects of CocaineWithdrawnPhase 1Christopher D. VerricoNCT06252623Written as Exenatide
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeCompletedPhase 3Baylor Research InstituteNCT02251431Written as BYDUREON
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)CompletedPhase 4Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNCT04897802Written as Experimental: GLP1-RA (exenatide) administration
- Diabetes Islet Preservation Immune TreatmentWithdrawnPhase 1/2Camillo Ricordi and Jay SkylerNCT02586831Written as Exenatide
- Brain Activation and Satiety in Children 2Active, not recruitingPhase 3Seattle Children's HospitalNCT04520490Written as Exenatide 2 mg [Bydureon]
- Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantCompletedPhase 1Vivani Medical, IncNCT05670379Written as Exenatide Implant
- Pharmacogenomics of GLP1 Receptor AgonistsTerminatedPhase 1University of Maryland, BaltimoreNCT05762744Written as Exenatide Injection (before the first FSIGT)
- Exenatide Once-weekly as a Treatment for Multiple System AtrophyCompletedPhase 2University College, LondonNCT04431713Written as Exenatide Pen Injector [Bydureon]
- GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryActive, not recruitingNot applicableRigshospitalet, DenmarkNCT02673931Written as Byetta (Lilly, Exenatide)
- Liver and Fat Regulation in Overweight Adolescent GirlsCompletedPhase 2/3University of Colorado, DenverNCT02157974Written as Byetta 5Mcg Pen Injection
- GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 DiabetesTerminatedPhase 4University at BuffaloNCT03029351Written as Exenatide Extended Release for Inj Susp 2 MG
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersCompletedNot applicableCambridge University Hospitals NHS Foundation TrustNCT03835013Written as Exenatide
- An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesCompletedNot applicableUniversity at BuffaloNCT02962492Written as Exenatide/Exenatide extended release
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)CompletedPhase 4University of WashingtonNCT01524705Written as Exenatide
- Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in GlucosuriaCompletedPhase 4The University of Texas Health Science Center at San AntonioNCT03331289Written as Exenatide
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DMCompletedPhase 4The University of Texas Health Science Center at San AntonioNCT02981069Written as Exenatide
See all 231 studies that test Exenatide →
Given in every arm · 4 — Exenatide is usual care beside what is tested
- Exenatide-test for Diagnosing Endogenous Hyperinsulinemic HypoglycemiaCompletedNot applicableUniversity Hospital, Basel, SwitzerlandNCT04909333Written as Exenatide
- GLP-1 Agonism for Blocking Cocaine Euphoria and Self-AdministrationCompletedPhase 1Yale UniversityNCT02302976Written as exenatide
- Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.CompletedPhase 4Bing HeNCT04969627Written as Exenatide
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsTerminatedPhase 3Universitätsklinikum Hamburg-EppendorfNCT03419624Written as Exenatide 2 mg [Bydureon]
As the comparator · 13 — what is tested is compared with Exenatide
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedPhase 3SanofiNCT02787551Written as exenatide
- Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT01885208Written as exenatide
- The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD TherapyCompletedPhase 3Novo Nordisk A/SNCT01676116Written as exenatide
- Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 DiabetesCompletedPhase 3AstraZenecaNCT01652716Written as Exenatide twice daily
- Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT00518882Written as exenatide
- Clinical Trial for PB-119 in Subjects With Type 2 Diabetes MellitusCompletedPhase 1PegBio Co., Ltd.NCT03059719Written as Exenatide injection(Byetta)
- Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 DiabetesCompletedPhase 1AstraZenecaNCT01664624Written as Exenatide
- GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of MetforminCompletedPhase 3SanofiNCT00707031Written as Exenatide
- A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.CompletedPhase 3Hoffmann-La RocheNCT00717457Written as exenatide
- A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly SuspensionCompletedPhase 2AstraZenecaNCT01104701Written as exenatide once weekly
- Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes MellitusCompletedPhase 2Intarcia TherapeuticsNCT00943917Written as Exenatide Injection
- A Study in Participants With Type 2 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01064687Written as Exenatide
- Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 DiabetesCompletedPhase 1Bristol-Myers SquibbNCT00508287Written as Byetta
Codes
What other systems call Exenatide · ClinicalTrials.gg INT006683
- MeSH (NLM) D000077270ExenatideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9P1872D4OLEXENATIDEConfirmed FDA, NLM
- RxNorm 60548One source FDA
- NCI Thesaurus C65611ExenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077270 | Exenatide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9P1872D4OL | EXENATIDE | Confirmed FDA, NLM |
| RxNorm | 60548 | — | One source FDA |
| NCI Thesaurus | C65611 | Exenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.